PTG-100

DRUG2 trials

Sponsors

Protagonist Therapeutics, Inc., Nielsen Fernandez-Becker

Conditions

Celiac DiseaseUlcerative Colitis

Phase 1

PTG-100 for Patients With Celiac Disease

CompletedNCT04524221

Nielsen Fernandez-BeckerCeliac Disease

Start: 2021-02-26End: 2022-04-03Updated: 2022-05-23

Phase 2

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

TerminatedNCT02895100

Protagonist Therapeutics, Inc.Ulcerative Colitis

Start: 2016-12-31End: 2018-03-26Updated: 2025-08-21

Related Papers

PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.

2021-08-3027 citations